Prognostic value of site-specific metastases in lung cancer: A population based study
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (14) , 3079-3086
Abstract
Background: Studies on prognosis of different metastasis sites in patients with lung cancer are limited. The aim of present study was to investigate the prognostic value of metastases sites among patients with metastatic lung cancer.Keywords
This publication has 32 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Specific organ metastases and survival in small cell lung cancerOncology Letters, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Non-small cell lung cancer and silent brain metastasisLung Cancer, 2009
- Postrecurrence survival in patients with stage I non-small cell lung cancerEuropean Journal of Cardio-Thoracic Surgery, 2008
- Population Characteristics and Prognostic Factors in Metastatic Non–Small-Cell Lung Cancer: A Fox Chase Cancer Center RetrospectiveClinical Lung Cancer, 2008
- Pathologic fractures correlate with reduced survival in patients with malignant bone diseaseCancer, 2007
- National survey of non-small cell lung cancer in the United States: Epidemiology, pathology and patterns of careLung Cancer, 2007